Abstract:Objective For major depressive disorder (MDD), there has been a lack of neuroimaging markers of efficacy of pharmacological treatment. In this study, we aimed to explore the neuroimaging mechanisms in patients with first-episode MDD and identify markers that predict the efficacy of 5-hydroxytryptamine reuptake inhibitors (SSRIs) with the use of resting-state brain imaging technology. Methods A total of 101 patients with first-episode MDD and 53 normal controls were finally included in this study. Based on the reduction rate of the score of Hamilton Depression Rating Scale (HAMD-17) during the 2-week SSRI treatment, 31 patients were assigned into the unresponsive group and 32 were assigned into the responsive group. The brain function was compared between patients with MDD and normal controls, and the diagnostic value of brain function was analyzed. With brain regions showing differences between patients with MDD and normal controls as a mask, and the brain function between the responsive and unresponsive groups were compared. Correlations between brain function the HAMD-17 score reduction rate during the 2-week SSRI treatment were analyzed. Results Compared to normal controls, patients with MDD showed increased ReHo in the left parahippocampal gyrus and right parahippocampal gyrus, decreased ReHo in the right middle occipital gyrus, and decreased functional connectivity between the right and left parahippocampal gyri, right middle occipital gyrus and middle temporal gyrus. Receiver operator characteristic (ROC) curve analysis showed that the area under the curve (AUC) was 0.544 (95% CI: 0.445–0.644) for ReHo and 0.822 (95% CI: 0.734–0.909) for functional connectivity. Logistic regression pooling of the differences in ReHo mean time series with the functional connectivity mean time series was performed for the ROC curve analysis, which showed an AUC of 0.832 (95% CI: 0.752–0.911). Compared to the responsive group, the unresponsive group showed elevated ReHo in the right parahippocampal gyrus and lower functional connectivity in the middle temporal gyrus. We also found that the ReHo value was negatively correlated with the HAMD-17 score reduction after 2 weeks of SSRI treatment. Conclusion Altered resting-state brain function in some regions might be a neurobiological marker for the diagnosis of MDD, and ReHo values are expected to be predictors of patient response to treatment with SSRIs. Clinical Trial Registration [ http://www.chictr.org.cn/ ], identifier [ChiCTR1900028722].

SSRI Treatment Response Prediction in Depression Based on Brain Activation by Emotional Stimuli

Emotion-based brain mechanisms and predictors for SSRI and CBT treatment of anxiety and depression: a randomized trial

Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder

Predicting Antidepressant Citalopram Treatment Response via Changes in Brain Functional Connectivity After Acute Intravenous Challenge

Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression

Predicting Escitalopram Monotherapy Response in Depression: the Role of Anterior Cingulate Cortex

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder

Predict Value of Functional Topological Features for Early Response to Antidepressant Treatment in Major Depressive Disorder

Prefrontal cortex engagement during an fMRI task of emotion regulation as a potential predictor of treatment response in borderline personality disorder

Neural predictors of treatment response to brain stimulation and psychological therapy in depression: a double-blind randomized controlled trial

Brain regulation of emotional conflict predicts antidepressant treatment response for depression

Distinct Features of Cerebral Blood Flow and Spontaneous Neural Activity as Integrated Predictors of Early Response to Antidepressants.

Pretreatment predictors of early response revealed by quantitative cerebral blood flow in major depressive disorder

Neural responses to facial emotions and subsequent clinical outcomes in difficult-to-treat depression

Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine

Connectivity of the Cognitive Control Network During Response Inhibition as a Predictive and Response Biomarker in Major Depression: Evidence From a Randomized Clinical Trial

Predictive modeling of antidepressant efficacy based on cognitive neuropsychological theory

Contribution of resting-state functional connectivity of the subgenual anterior cingulate to prediction of antidepressant efficacy in patients with major depressive disorder

Neural responses with happy emotional processing of patients with first-onset major depressive disorder by antidepressant treatment investigated with functional MRI

Improving Therapy Outcome Prediction in Major Depression Using Multimodal Functional Neuroimaging: A Pilot Study

Whole-brain turbulent dynamics predict responsiveness to pharmacological treatment in major depressive disorder